Quantexa Appoints Industry Luminaries to its Advisory Board to Accelerate Growth Plans
22 sept. 2023 01h00 HE
|
Quantexa
LONDON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Quantexa, the global leader in Decision Intelligence (DI) solutions for the private and public sectors, announced today that it has appointed three...
Aptose to Present at the Cantor Global Healthcare Conference
18 sept. 2023 07h45 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
24 août 2023 07h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
14 août 2023 16h30 HE
|
Marker Therapeutics
Executed comprehensive non-dilutive agreement with Cell ReadyTM, resulting in an extended financial runway into the fourth quarter of 2025 Appointed Juan Vera, M.D. as President and Chief Executive...
Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update
10 août 2023 16h05 HE
|
Vor Biopharma
Next trem-cel clinical data update expected by year-end 2023VCAR33ALLO IND cleared by U.S. FDA; Rapidly activating sites toward study initiationSecured non-exclusive license to Cas9 gene-edited HSCs ...
Aptose Reports Results for the Second Quarter 2023
10 août 2023 16h02 HE
|
Aptose Biosciences, Inc.
─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─ ─ CRc 44% in Patients Who Failed Prior Venetoclax ── CRc 43% in Patients with Wildtype FLT3 ── CRc 67%...
Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference
01 août 2023 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will host in-person 1x1 investor meetings at the 2023 Wedbush PacGrow...
Quantexa Bringing Total Global Investment in Artificial Intelligence Research and Development to Over $250M by 2027
09 juil. 2023 19h01 HE
|
Quantexa
Quantexa CEO outlines vision for investment in support of UK Government’s plan to make UK an AI Hub, which includes: Over $155M in new global investments aimed at accelerating enterprise...
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
26 juin 2023 07h00 HE
|
Marker Therapeutics
HOUSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR) (Marker or the Company), a clinical-stage immuno-oncology company focusing on developing next-generation T...
Aptose Presents Highlights from Clinical Update
10 juin 2023 12h00 HE
|
Aptose Biosciences, Inc.
Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML PatientsFavorable safety with monotherapy responses across four dose levels with no DLT in mutationally diverse and difficult to treat...